Isoforms of free prostate-specific antigen

Isoforms of free prostate-specific antigen

Diğer sürümleri göster (1)

Detection of prostate-specific antigen remains the mainstay in the early detection of prostate cancer. A problem yet unsolved is the lack of specificity of this organ- but not cancer-specific marker, which generates subsequent, invasive procedures in a high number of patients without detecting prost...

Detaylı Bibliyografya
Asıl Yazarlar:	Haese, A, Noldus, J, Steuber, T, Huland, H, Lilja, H
Materyal Türü:	Journal article
Dil:	German
Baskı/Yayın Bilgisi:	2004

Benzer Materyaller

[Isoforms of free prostate-specific antigen]
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Total and gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen.
Yazar:: Steuber, T, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy.
Yazar:: Steuber, T, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer.
Yazar:: Steuber, T, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue.
Yazar:: Steuber, T, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml.
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer.
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Discrimination of prostate cancer from benign disease by selective measurements of serum subfractions of free PSA that are not internally cleaved at Lys145-Lys146
Yazar:: Nurmikko, P, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum.
Yazar:: Steuber, T, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen.
Yazar:: Aalamian, M, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.
Yazar:: Becker, C, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer.
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Biology of prostate-specific antigen
Yazar:: Lilja, H
Baskı/Yayın Bilgisi: (2003)

Biology of prostate-specific antigen.
Yazar:: Lilja, H
Baskı/Yayın Bilgisi: (2003)

Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.
Yazar:: Végvári, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum.
Yazar:: Piironen, T, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade.
Yazar:: Haese, A, ve diğerleri
Baskı/Yayın Bilgisi: (2005)

Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen.
Yazar:: Christensson, A, ve diğerleri
Baskı/Yayın Bilgisi: (2010)

Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio.
Yazar:: Aus, G, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone.
Yazar:: Evans-Axelsson, S, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Increase in percent free prostate-specific antigen in men with chronic kidney disease.
Yazar:: Bruun, L, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Prostate-specific antigen and prostate cancer: prediction, detection and monitoring.
Yazar:: Lilja, H, ve diğerleri
Baskı/Yayın Bilgisi: (2008)

Prediction of tumor heterogeneity in localized prostate cancer.
Yazar:: Huland, H, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Variation in percentage-free prostate-specific antigen (PSA) with prostate volume, age and total PSA level.
Yazar:: Törnblom, M, ve diğerleri
Baskı/Yayın Bilgisi: (2001)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer
Yazar:: Becker, C, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer.
Yazar:: Becker, C, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.
Yazar:: Bruun, L, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.
Yazar:: Botchorishvili, G, ve diğerleri
Baskı/Yayın Bilgisi: (2009)

Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden.
Yazar:: Hugosson, J, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3).
Yazar:: Aus, G, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater.
Yazar:: Becker, C, ve diğerleri
Baskı/Yayın Bilgisi: (2000)

Circulating biomarkers for prostate cancer.
Yazar:: Steuber, T, ve diğerleri
Baskı/Yayın Bilgisi: (2007)

Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.
Yazar:: Bruun, L, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
Yazar:: Vickers, A, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen.
Yazar:: Olsson, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.
Yazar:: Ulmert, D, ve diğerleri
Baskı/Yayın Bilgisi: (2012)

Molecular insights into substrate specificity of prostate specific antigen through structural modeling.
Yazar:: Singh, P, ve diğerleri
Baskı/Yayın Bilgisi: (2009)